
    
      A randomized, double-blind, placebo-controlled 12-week study with GLP-1 analogue
      (semaglutide) in men and women with obesity (BMI 30-49.9 kg/m2) in a validated laboratory
      model to identifying processes underlying greater food craving, intake and weight change, in
      order to test mechanisms by which a GLP-1 analogues may exerts significant weight effects in
      obesity.
    
  